VisionGate Updates

As VisionGate was preparing for a busy Fall season with the generation of clinical data for lung cancer screening using its LuCED test, the U.S. Preventive Services Task Force electrified the lung cancer community with its draft recommendation that older Americans at high risk of lung cancer get screened every year with a low-dose x-ray CT scan (for more on the recommendations, click here.)  This recommendation is based on a landmark NCI study showing that CT screening reduces lung cancer deaths by 20%. The report then went on to highlight the major disadvantage of CT screening, which is a high false positive rate.  High false positive results would generate a great deal of follow-up testing that is costly, burdensome and ultimately unnecessary, and they could result in fewer at-risk people receiving lung cancer screening.

 

One key message is that reimbursement for lung cancer screening is now emerging. The other is that the high rate of false positive results in CT screening is good news for VisionGate. This is because VisionGate’s LuCED test can be launched initially as a non-invasive, cost-effective adjunct to CT screening to pinpoint the true positives while minimizing the false positives – using CT scanning in conjunction with LuCED means that those patients receiving a positive result would actually have lung cancer. With this important development as context, VisionGate scientists will present the initial results of a pilot clinical study using LuCED and the Cell-CTTM 3D cell analysis system at the prestigious IASLC World Conference on Lung Cancer in late October.

 

In addition, VisionGate CEO Alan Nelson will discuss the Cell-CT technology as a keynote speaker at the Single Cell Analysis Summit in mid-September.  We also anticipate that VisionGate’s technology may again be featured in an upcoming Nature publication, one of the most respected science journals. We are looking forward to these opportunities to raise the profile of VisionGate’s breakthrough Cell-CT technology among key scientific and industry audiences, as the company advances its LuCED clinical program.




more No Comments August 19 2013


Dr. Alan Nelson named Research Fellow at International Prevention Research Institute

Dr. Alan Nelson, CEO of VisionGate, has been recently named a Research Fellow at International Prevention Research Institute.

The International Prevention Research Institute (iPRI) is an independent research institute with a staff of demonstrated world-class excellence and leadership. iPRI has unparalleled experience in epidemiological research and macro health planning with a record of delivering real health and economic value to a range of public and private sources including governments, universities, research institutes, non-governmental organisations and large multi-national concerns. More information can be found at the link above.

 



more No Comments August 7 2013


Game Changer for Lung Cancer Announced

NATIONAL EXPERT PANEL RECOMMENDS ANNUAL CT SCANS FOR THOSE AT HIGH RISK FOR LUNG CANCER; PUBLIC AND PRIVATE REIMBURSEMENTS EXPECTED TO FOLLOW RECOMMENDATION

 

 The USPSTF  issued a draft recommendation giving its second highest approval rating for CT screening for lung cancer for those at high risk, a move that if approved in final form, will trigger Medicare and insurance coverage and bring about a dramatic drop in the leading cause of cancer deaths.

Lung Cancer Alliance President and CEO Laurie Fenton-Ambrose said the implications of the favorable “B” rating are profound and a “monumental moment.”

“Tens of thousands of lives could be saved,” she said. “Screening those at high risk now will dramatically make a difference and will open the door to much faster advances in research on all stages of lung cancer. This is a game changer.”

The USPSTF recommends screening for current and former smokers ages 55 to 80 with a smoking history the equivalent of smoking a pack a day for 30 years or two packs a day for 15 years. The recommendation for screening includes those who have quit within the past 15 years.

“The most important next steps are to help educate the public about risk and to direct them to responsible screening,” said Fenton Ambrose. “We are here to answer questions about lung cancer risks and provide information to those who need it most.”

Now that USPTSF has issued its draft recommendation, public comments are invited and will be accepted until August 26, 2013. The recommendation is expected to be finalized within six months.



more No Comments August 7 2013


Columnar Cell

The cell is shown in maximum intensity projection. In the center and right panels, color and opacity have been adjusted to render the cytoplasm in translucent white, the nucleus in opaque blue and the interior of the nucleus in a green to red chromatic gradient with the nucleoli rendered in opaque red.  Individual cillia are approximately 0.2 microns in diameter. Observation of individual cillia in the video indicates that Cell-CT resolution is at least one-half micron.> Read More



more No Comments May 17 2011


Adenocarcinoma

The cell is shown in maximum intensity projection. In the center and right panels, color and opacity have been adjusted to render the cytoplasm in translucent white, the nucleus in opaque blue and the interior of the nucleus in a green to red chromatic gradient with the nucleoli rendered in opaque red. > Read More



more No Comments May 17 2011


Cell-CT

The Cell-CT™ uses a technique called Optical Projection Tomography to render cells in 3D. This process is illustrated in the video where a cell is shown transported through the Cell-CT’s glass micro-capillary by applying pressure to a gel that embeds cells. As the capillary spins, the cell is scanned from multiple perspectives creating images that are then used to form a 3D image of the Cell. > Read More



more No Comments May 17 2011


Welcome to VisionGate

VisionGate is dedicated to saving lives through early cancer detection and prevention.  The Cell-CT™ is a revolutionary automated 3D cell imaging platform that generates high-resolution 3D biosignatures from intact cells.



more No Comments May 12 2011



Copyright 2019 - VisionGate, Inc.